Brands

Features

Oral JAK inhibitors unlikely to be totally shut out in eczema by black box warning

Dermatologists point to several uptake openings for JAK inhibitors in moderate-to-severe eczema despite highly publicized side effect concerns.

Reynald Castañeda
Features

Regulatory roundup: Ology, MaxCyte make moves in women’s cancer with divergent approval chances

Features

Gilead’s lenacapavir: HIV prospects strongest in long-acting combos with Merck’s islatravir

Features

Akebia and GSK will grapple with heightened scrutiny of HIF PHIs after roxadustat concerns

Features

Regulatory roundup: Sanofi/Regeneron, J&J and Eyenovia boost approval chances with Phase III updates

Features

Trial of AbbVie’s NASH drug against severe Covid-19 enrols 25% of patients after a year